Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 6 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
The True Obesity Paradox: Obese and Malnourished?
Author(s): Mohammed El-Sheikh , Nora Olsen El Caidi , Aginsha Kandiah , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
TTR Therapies Show Delayed Mortality Benefit in ATTR-CM
Added: 2 months ago Source:  Radcliffe Cardiology
Therapies for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including transthyretin (TTR) stabilisers and silencers, have demonstrated a mortality benefit in randomised trials. However, the timing of this benefit has been a subject of debate. A new analysis of three major outcomes trials has evaluated this time course, revealing a consistent pattern across different treatments… View more

Heart Failure
RDW Prognostic Marker in HF and Predictor for Iron Replacement Responsivene
Author(s): Artemio García-Escobar , Rosa Lázaro-García , Javier Goicolea-Ruigómez , et al Added: 1 year ago

Heart Failure
Intravenous Ferric Carboxymaltose in FAIR-HF2 Trial Shows No Significant Reduction in Heart Failure Events but Improves Quality of Life
Added: 11 months ago Source:  Radcliffe Cardiology
AUTHOR: Sean DelaneyIn the landmark FAIR-HF2 randomized clinical trial (NCT03036462)1, intravenous (IV) ferric carboxymaltose did not significantly reduce heart failure (HF) hospitalizations or cardiovascular deaths in patients with heart failure and iron deficiency, despite improving patient-reported quality of life outcomes. Results were presented at ACC.252 and concurrently published in JAMA3… View more

Heart Failure
Dan Lenihan
Research Area(s) / Expertise: Job title: Cardio-oncologist
Dr Dan Lenihan is a cardio-oncologist specialising in cardiology, heart disease and advanced heart failure, atSaint Francis Healthcare System, Cape Girardeau, US.He is a co-Founder and Board Member of the International Cardio-Oncology Society (ICOS), which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.He is… View more
Defining AF Cardiomyopathy
Author(s): Nikhil Ahluwalia , Shohreh Honarbakhsh , Ross Hunter , et al Added: 1 month ago

Electrophysiology & Arrhythmia

Heart Failure
Transvenous Phrenic Nerve Stimulation in Central Sleep Apnoea/Heart Failure
Author(s): Tarek Bekfani , Joseph D Abraham , William T Abraham Added: 7 months ago

Heart Failure
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
Author(s): Michael R Zile Added: 1 year ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had… View more

Heart Failure
PREVENT Equations Define 30-Year CVD Risk Percentiles
Added: 4 months ago Source:  Radcliffe Cardiology
Communicating long-term cardiovascular disease (CVD) risk to younger adults can be challenging, but new research offers a tool to frame risk relative to an individual's peers. Investigators have developed population-based, age- and sex-specific percentiles for 30-year risk of CVD, atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF) using the PREVENT (Predicting Risk of CVD… View more

Prevention & Chronic Conditions

Demographic